Modulators of the urokinase-type plasminogen activation system for cancer

Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor

(2010) Xian-wen Hu et al.   CANCER BIOLOGY & THERAPY

Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group

(2009) Ralf Hildenbrand et al.   AMERICAN JOURNAL OF PATHOLOGY

Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver

(2009) George Van Buren et al.   CANCER

Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor

(2009) Yuqi Jing et al.   CANCER RESEARCH

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

(2009) Salvatore Ulisse et al.   CURRENT CANCER DRUG TARGETS

Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives

(2009) M. Sienczyk et al.   CURRENT MEDICINAL CHEMISTRY

The urokinase plasminogen activator system in cancer: A putative therapeutic target?

(2009) S. Killeen et al.   DRUG NEWS & PERSPECTIVES

Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice

(2008) Michihiro Mutoh et al.   CARCINOGENESIS

Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator†

(2007) Martyn Frederickson et al.   JOURNAL OF MEDICINAL CHEMISTRY